Cellectricon presents transfection solutions for drug discovery at Experimental Biology 2013
Mölndal, Sweden, April. 17, 2013
Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be exhibiting its revolutionary in-situ transfection technology platforms on booth #1178 at the Experimental Biology conference (20-24 April, Boston, US). Cellectricon will also present two posters on April 24, focusing on high performance in-situ transfection. The poster “Transfection of primary and iPSC-derived cells by capillary electroporation” (LB162) explores how Cellectricon’s novel electroporation Cellaxess® ACE system is ideal for in-situ transfection of any adherent cell type. Minimal cell processing and low voltages ensure excellent viability and completely retained morphology, in any cell culture format.
For in-situ transfection applications on a larger scale, the poster “High throughput in-situ transfection of primary and iPSC-derived cells” (LB163) details how the novel electroporation platform Cellaxess® Elektra is optimized for in-vitro transfection of primary and iPSC-derived cells, directly into 384-well plates. With virtually no impact on cell viability or morphology, this system is ideal for screening applications such as cDNA and RNAi. The presentations will commence from 12:15 to 13:30, and posters will be available for viewing throughout the day.
For more information on the Cellaxess ACE, Cellaxess Elektra and Cellectricon’s Discovery Services, visit www.cellectricon.com